TRIP-1 via AKT modulation drives lung fibroblast/myofibroblast trans-differentiation by Michael F Nyp et al.
Nyp et al. Respiratory Research 2014, 15:19
http://respiratory-research.com/content/15/1/19RESEARCH Open AccessTRIP-1 via AKT modulation drives lung fibroblast/
myofibroblast trans-differentiation
Michael F Nyp1,2, Angels Navarro1,2, Mohammad H Rezaiekhaligh1,2, Ricardo E Perez1,2, Sherry M Mabry1,2
and Ikechukwu I Ekekezie1,2*Abstract
Background: Myofibroblasts are the critical effector cells in the pathogenesis of pulmonary fibrosis which carries a
high degree of morbidity and mortality. We have previously identified Type II TGFβ receptor interacting protein
1 (TRIP-1), through proteomic analysis, as a key regulator of collagen contraction in primary human lung fibroblasts—
a functional characteristic of myofibroblasts, and the last, but critical step in the process of fibrosis. However, whether
or not TRIP-1 modulates fibroblast trans-differentiation to myofibroblasts is not known.
Methods: TRIP-1 expression was altered in primary human lung fibroblasts by siRNA and plasmid transfection.
Transfected fibroblasts were then analyzed for myofibroblast features and function such as α-SMA expression,
collagen contraction ability, and resistance to apoptosis.
Results: The down-regulation of TRIP-1 expression in primary human lung fibroblasts induces α-SMA expression
and enhances resistance to apoptosis and collagen contraction ability. In contrast, TRIP-1 over-expression inhibits
α-SMA expression. Remarkably, the effects of the loss of TRIP-1 are not abrogated by blockage of TGFβ ligand
activation of the Smad3 pathway or by Smad3 knockdown. Rather, a TRIP-1 mediated enhancement of AKT
phosphorylation is the implicated pathway. In TRIP-1 knockdown fibroblasts, AKT inhibition prevents α-SMA
induction, and transfection with a constitutively active AKT construct drives collagen contraction and decreases
apoptosis.
Conclusions: TRIP-1 regulates fibroblast acquisition of phenotype and function associated with myofibroblasts. The
importance of this finding is it suggests TRIP-1 expression could be a potential target in therapeutic strategy aimed
against pathological fibrosis.
Keywords: Type II TGFβ receptor interacting protein 1 (TRIP-1), Eukaryotic translation initiation factor-3 (eIF3),
Pulmonary fibroblasts, α-smooth muscle actin (α-SMA), FibrosisBackground
Fibrosis, a pathobiological process resulting in tissue re-
modeling from overabundant extracellular matrix depos-
ition, is a major cause of morbidity and mortality.
Myofibroblasts are considered chief perpetrators of this
pathology. Myofibroblasts are a trans-differentiated fibro-
blast phenotype, identified by alpha smooth muscle actin
(α-SMA) expression [1,2]. They are avid extracellular
matrix synthesizers and have enhanced collagen contrac-
tion ability. Myofibroblasts are more resistant to apoptotic* Correspondence: iekekezie@cmh.edu
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unless otherwise stated.signaling/induction than fibroblasts. This is particularly im-
portant because a failure of proper apoptotic termination, a
consequence of an inability of epithelial cells to successfully
restore damaged epithelium, is a significant contributor to
pathological fibrosis. Regulation of fibroblast acquisition of
this trans-differentiated phenotype is a complex process mod-
ulated at multiple levels: transcriptional, translational, and
post-translational. Factors driving this trans-differentiation
include transforming growth factor β1 (TGFβ1) ligand
which has also been implicated as a central mediator of fi-
brosis and has been shown to induce α-SMA expression
in TGFβ1-treated fibroblasts [3-14].
Type II TGFβ receptor interacting protein-1 (TRIP-1) is
a WD-40-containing endogenous protein. It was initially. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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receptor kinase capable of modulating TGFβ1 response,
but later as a functional component of eukaryotic transla-
tion initiation factor-3 (eIF3) multi-protein complexes
[15-17]. However, unlike most other eIF3 component pro-
teins, it was shown to also exist independently in the cyto-
plasm, free from eIF3 complex, suggesting TRIP-1 may
interact with other factors and have functions not related to
protein translation [15,18,19]. Indeed, Shue et al. demon-
strated that TRIP-1 can bind tartrate-resistant acid phos-
phatase (TRAP) in osteoblasts causing cytodifferentiation
to osteoclasts [20]. More recently they showed that TRIP-1
is secreted in the provisional bone matrix and is not only
present in the cytosol, but also in the nucleus of osteoblasts
[21]. We have reported that TRIP-1 is a negative regulator
of fibroblast collagen contraction and modulates epithelial-
mesenchymal transition (EMT) of lung epithelial cells,
which would suggest it has the potential to influence execu-
tion of fibrotic pathology [22-24]. Myofibroblasts are the
critical effector cells in the pathogenesis of fibrotic remodel-
ing, but whether or not TRIP-1 modulates fibroblast trans-
differentiation to a myofibroblast phenotype has not been
explored.
In the current work, we report that down-regulation
of TRIP-1 expression in primary human lung fibroblasts
has the promotive effect of inducing trans-differentiation
to the myofibroblast phenotype, while over-expression
has inhibitory effects. Remarkably, the effects of down-
regulating TRIP-1 were not abrogated by blockage of
TGFβ1 ligand Smad3 activation, or by knocking-down
Smad3 expression. Moreover, loss of TRIP-1 enhanced
the ability to resist apoptosis and collagen contraction
ability in the cells. This effect we uncovered is due to a
TRIP-1 dependent rise in the phosphorylated-AKT levels
that promotes accumulation of α-SMA and prolongs cell
survival in a collagen matrix. These findings are import-
ant because they reveal TRIP-1 in a novel regulatory role
of modulating fibroblast acquisition of phenotype and
function associated with myofibroblasts, which may have
implications for development of potential therapies for
pathological fibrosis.
Methods
Study was performed using commercially available hu-
man fibroblast cell lines. No animal or human subjects
were enrolled or used in this study thus IRB or IACUC
approvals were not applicable.
Cells, reagents
Human Lung Fibroblasts of fetal (HLF-F) or adult (HLF-A)
origin were purchased from Cell Applications, Inc. (San
Diego, CA) and grown in HLF growth media (used pas-
sages 3–5). SB-431542 was from Sigma-Aldrich (St. Louis,
MO), Akt inhibitor II from Calbiochem (EMD Millipore,Billerica, MA) and Rhodamine-Phalloidin was from Cystos-
keleton, Inc. (Denver, CO).
siRNA-mediated gene silencing
TRIP-1 (siRNA ID no. 13735), control (siRNA-1 AM4611)
and Smad3 (siRNA ID no. s8400) were from Ambion (Ap-
plied Biosystems, Austin, TX). HLF-F were transfected with
Lipofectamine RNAiMAX (Life Technologies, Carlsbad,
CA), according to the manufacturer’s protocol, to final con-
centration 50 nM of control or TRIP-1 (EIF3I) siRNA. For
some experiments Smad3 siRNA was added (5 nM). Ly-
sates or set-up of collagen contraction assays was per-
formed 2 days after transfection.
Plasmid-mediated AKT/TRIP-1 over-expression
An active-form AKT plasmid (pSG5-AKT) was a gift
from Dr A. C. Larner (developed by Burgering and
Coffer [25]). pcDNA4/hTRIP-1-V5/His and pcDNA4/
LacZ were generated using pcDNA4/TO/myc-His vector
from Life Technologies (Carlsbad, CA). For AKT, 70%
confluent HLF-F were transfected with Lipofectamine
and Plus reagent according to instructions, trypsinized
24 hours later and embedded in collagen for contraction
or apoptosis analysis. For TRIP-1, HLF-A cells were
starved in 0.5% FBS-containing media, treated with 5
ng/ml TGF-1 in 0.5% FBS-media for 24 hours and trans-
fected with jetPRIME (Polyplus-Transfection Inc., New
York, NY) according to manufacturer’s instructions.
Cells were plated onto glass coverslips 24 hours later,
and stained 24 hours later.
TGFβ receptor and Akt inhibitor
TRIP-1 siRNA-transfected HLF-F were treated with vehicle
(DMSO) or with 10 μM solution of TGFβ receptor inhibi-
tor SB431542 in DMSO for 24 hours. This concentration of
SB431542 has been shown to block TGFβ1 ligand signaling
[24,26]. For Akt inhibition, Akt inhibitor II at 40 μM was
added immediately after transfection and left 48 hours. This
concentration has been shown to inhibit Akt activity in
cells [27].
Collagen contraction
Type I collagen gels were prepared by mixing cold rat tail
HC collagen (BD Biosciences) with 10X DMEM (Sigma-
Aldrich, St Louis, MO) on ice, neutralizing with 1 M NaOH
and diluting to 1 mg/ml collagen. Fibroblasts were trypsi-
nized, resuspended in cold, serum-free DMEM, and added
to the collagen mixture at a final concentration of 5 × 105
cells/ml with 0.75 mg/ml as final collagen concentration
[22]. Aliquots (in triplicate) were cast onto 24-well plates
and allowed to solidify at 37°C (30–45 minutes), after which
serum-free media was added, incubated, periodically ob-
served for contraction, and photographed. Experiments
were performed a minimum of three times.
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Total cell lysates were prepared (unless specified in figure
legend), and proteins were separated by SDS-PAGE, trans-
ferred to PVDF membranes and detected with ECL from
GE Healthcare Biosciences (Piscataway, NJ) as previously
described [22], using polyclonal rabbit anti-TRIP-1 from
Abcam (1:1000), mouse monoclonal antibodies against
smooth muscle actin (1:1000) and tubulin (1:10000) from
Sigma-Aldrich and P-Ser473-Akt (1:1000), Smad3 (rabbit
monoclonal C67H9, 1:1000), Cleaved Caspase-3 (rabbit
monoclonal D175, clone 5A1E, 1:1000 using nitrocellulose
0.2 μm pore size instead of PVDF membranes) from Cell
Signaling Technologies, and anti-actin (polyclonal goat I-
19, 1:1000) from Santa Cruz Biotechnologies (Santa Cruz,
CA). Western-blots were developed using ECL (chemilu-
minescence), and densitometric scans were quantified using
Alpha-Innotech and AlphaEaseFC Imaging Software (Pro-
tein Simple, Santa Clara, CA).
Immunofluorescence
Coverslips were rinsed with warm PBS, then cells were
fixed using 3.7% paraformaldehyde in PBS for 10 minutes
at room temperature, rinsed twice with PBS, permeabilized
with 0.1% Triton X-100 in PBS for 5 minutes and rinsed
twice with PBS again. Cells were then stained with
Rhodamine-Phalloidin from Cytoskeleton, Inc (Denver,
CO) according to manufacturer’s recommendations (3–5
units/coverslip, in PBS containing 0.5% BSA, for 30 minutes
at room temperature). After rinsing twice with PBS, stain-
ing for V5-TRIP-1 was performed after blocking with 3%
BSA in PBS, using a mouse monoclonal antibody against
V5 (Life Technologies, (Carlsbad, CA)) at a 1/500 dilution,
after which cells were rinsed, incubated with a secondary
anti-mouse AlexaFluor-488 from Life Technologies
(Carlsbad, CA), and then coverslips were mounted onto
slides using DAPI-containing Vectashield (Vector La-
boratories, Burlingame, CA) after three washes in PBS.
For α-SMA staining, a rabbit antibody from Abcam Ltd
(Cambridge, MA) was used at 1/500 dilution in conjunc-
tion with the V5 antibody, and a secondary anti-rabbit
Alexa Fluor 564. Pictures were taken using a CCD camera
coupled to an Olympus BX60 fluorescence microscope.
TUNEL assay
Twenty-four hours following siRNA transfection, fibro-
blasts were embedded into collagen gels and, at the ap-
propriate times, fibroblasts were analyzed for apoptosis
using an in situ cell death detection kit (fluorescence
TUNEL assay from Roche Applied Science, Indianapolis,
IN) according to manufacturer’s instructions. Briefly,
gels were collected, treated at 60°C for 10 minutes, then
samples were spun down 3 minutes at 400×g to collect
cells, washed with 10% FBS-containing media, then
plated onto glass slides using a cytospin; recovered cellswere fixed with 4% paraformaldehyde for 1 hour at room
temperature and permeabilized with 0.1% Triton X-100
for 2 minutes at 4°C. TUNEL reaction mixture was
added to the cells, incubated for 60 minutes at 37°C in
the dark, washed twice with PBS, then mounted with
coverslips using Vectashield with DAPI, and analyzed by
fluorescence microscopy.
Statistical analysis
Results are expressed as means ± SE of data obtained.
Statistical analysis was performed with student’s t-test
for paired comparisons. A value of P < 0.05 was consid-
ered significant.
Results
Loss of TRIP-1 in human lung fibroblasts induces alpha-
smooth muscle actin expression promoting myofibroblast
phenotype and function
Alpha-smooth actin (α-SMA), a hallmark of myofibroblasts,
plays a central role in forming stress fibers, and its level of
expression is reported to correlate with the ability of (myo)
fibroblasts to contract collagen [1]. We previously found
that fetal human lung fibroblasts (HLF-F) lesser ability for
collagen contraction is due to higher TRIP-1 protein ex-
pression [22]. To assess whether TRIP-1 drives fibroblast
acquisition of myofibroblast phenotype and function in hu-
man lung fibroblasts, TRIP-1 siRNA-transfected versus
control siRNA-transfected HLF-F were embedded in a 3D
collagen matrix and studied for collagen contraction re-
sponse and α-SMA expression. As shown in Figure 1A and
Figure 1B, TRIP-1 siRNA transfection of HLF-F shows en-
hanced collagen contraction when compared to the control
siRNA-transfected HLF-F. Furthermore, α-SMA expression
was higher in the TRIP-1 siRNA-transfected fibroblasts
when compared to control siRNA-transfected fibroblasts,
as shown in Figure 1C and Figure 1D. In addition, TRIP-1
siRNA transfected HLF-F showed increased caldesmon and
calponin expression (Additional file 1: Figure S1). Import-
antly, the increase in α-SMA expression was present at
the mRNA level, as detected by real-time PCR analysis
(Figure 1E). Because TRIP-1 is known to regulate TGFβ
signaling and TGFβ signaling plays an important role
in regulating α-SMA expression, we evaluated PAI-1 and
CTCF gene expression to assess TGFβ pathway activation.
Interestingly, PAI-1 and CTCF mRNA expression in
TRIP-1-transfected fibroblasts was lower at baseline
but showed a robust response when exposed to TGFβ
when compared to control siRNA-transfected fibroblasts
(Additional file 1: Figure S2).
α-SMA expression mediated by loss of TRIP-1 is mostly
independent of TGFβ1 signaling
Activation of TGFβ1 signaling in fibroblasts leads to















































































Figure 1 Loss of TRIP-1 in human lung fetal fibroblasts enhances collagen contraction ability and induces expression of alpha-smooth
muscle actin (α-SMA). A: Collagen contraction assays using HLF-F transfected with control siRNA (left) or TRIP-1 siRNA (right) at 7 days; B: % area
contracted respect to original area is shown based on analysis of images like the ones shown in A) with means ± SE shown (**P < 0.05, n = 6);
C: analysis of α-SMA expression in HLF-F cells transfected with control or TRIP-1 siRNA (100 nM); cells were transfected and 48 h later lysates were
made and analyzed by western blot for TRIP-1, α-SMA and α-Tubulin (as a loading control); D: normalized values of TRIP-1 expression (black
boxes) or α-SMA expression (hatched boxes) in control siRNA (left) or TRIP-1 siRNA (right) transfected cells, with means ± SE shown (**P < 0.05,
n = 3); E) analysis of α-SMA mRNA expression by real-time PCR in control siRNA or TRIP-1 siRNA. Values are normalized to GAPDH mRNA.
Experiments were performed at least three times and one representative experiment is shown, with means ± SE shown (**P < 0.05, n = 3).
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regulatory role TRIP-1 has in TGFβ1 signaling [17].
Therefore, we assessed whether TRIP-1 effects on colla-
gen contraction and α-SMA expression were due to its
known regulatory role on TGFβ1 signaling. We blocked
TGFβ1 signaling using SB431542, a TGFβ receptor 1 in-
hibitor, in TRIP-1 siRNA-transfected HLF-F. However,
α-SMA expression remained elevated in the TRIP-1
siRNA-transfected HLF-F treated with SB431542 when
compared to TRIP-1 siRNA-transfected HLF-F treated
with vehicle (Figure 2A and Figure 2B). To confirm that
the TRIP-1 role in α-SMA accumulation was independ-
ent of Smad3 activation, we blocked Smad3 signaling by
siRNA Smad3 transfection in TRIP-1 siRNA-transfected
HLF-F. Persistent α-SMA expression was observedfollowing double transfection of these HLF-F when com-
pared to controls (Figure 2C and Figure 2D), suggesting
TRIP-1 regulates α-SMA expression through a TGFβ1
ligand independent mechanism. To further assess the
role TRIP-1 has on regulating α-SMA expression and its
ability to modify α-SMA expression in fibroblasts that
have already been induced with TGFβ1, we treated adult
HLF with TGFβ1 followed by V5-TRIP-1 transfection. As
shown in Figure 3A, staining of V5-TRIP-1-transfected,
TGF-β1- treated fibroblasts with V5 and α-SMA anti-
bodies demonstrated a decreased expression of α-SMA in
transfected cells compared to cells that do not express V5-
TRIP-1, and a decrease of actin stress-fibers detected with
Rhodamine-Phalloidin in the V5-TRIP-1-expressing cells
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Figure 2 Effect of loss of TRIP-1 on α-SMA expression is independent of TGFβ receptor signaling and Smad3. A: HLF-F transfected with
control siRNA or TRIP-1 siRNA were treated with either vehicle or with 10 μM solution of TGFβ receptor inhibitor (SB431542) for 24 h, after which
whole cell lysates were prepared and samples run on SDS-PAGE and analyzed by western-blot for α-SMA protein; Western blot shows a reduction
in TGFβ- induced α-SMA in controls treated with SB431542, while the α-SMA was not significantly different in the TRIP-1 siRNA treated fibroblasts
when treated with SB431542. TGFβ1 treatment was used as a positive control for the inhibitor; α-Tubulin was used as a loading control;
B: normalized values of α-SMA expression in control siRNA (left) or TRIP-1 siRNA (right) transfected cells, with means ± SE shown (**P < 0.05, n = 3)
showing a significant difference in TGFβ-induced α-SMA in the controls when treated with SB431542 but no difference in the TRIP-1 siRNA
fibroblast treated with SB431542; C: HLF-F cells were transfected with control siRNA, TRIP-1 siRNA or TRIP-1 and Smad3 siRNA and 48 hours later
lysates were prepared and analyzed by western-blot for α-SMA expression showing increased α-SMA in TRIP-1 siRNA is independent of Smad3 activity;
D: normalized values of α-SMA expression in control siRNA (left column), TRIP-1 siRNA (middle column) or TRIP-1 and Smad3 siRNA (right column)
transfected cells, with means ± SE shown (**P < 0.05, n = 3). Experiments were performed three times and one representative experiment is shown.
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in human lung fibroblasts.
Loss of TRIP-1 leads to prolonged cell survival and resist-
ance to apoptosis in human lung fibroblasts
The ability of myofibroblasts to resist apoptosis signaling
is linked to the development of pathological fibrosis,
while the termination of fibroblast contractility response
is important for nonfibrotic wound healing. To assess
the role of TRIP-1 expression in fibroblast apoptosis re-
sponse, we analyzed the degree of apoptosis by TUNEL
assay between the TRIP-1 siRNA-transfected and control
siRNA-transfected HLF-F after 5 days in the collagen
gel. As seen in Figure 4A and 4B, the percentage of
TUNEL-positive nuclei was significantly lower in the
TRIP-1 siRNA-transfected HLF-F when compared to thecontrol siRNA-transfected HLF-F, suggesting TRIP-1 is a
negative regulator of fibroblast apoptosis. Apoptosis was
also detected using western-blot in samples from cells
embedded in collagen gels (Figure 4C). At 24 and
48 hours after embedding in collagen, control siRNA-
transfected cells show detectable levels of cleaved cas-
pase 3 by Western-blot, which is absent in the TRIP-1
siRNA-transfected cells.
TRIP-1 depleted fetal human lung fibroblasts have
increased phosphorylated AKT levels and loss of AKT
signaling negates the regulatory role of TRIP-1 on α-SMA
expression
Fibroblast apoptosis signaling occurs through many
pathways, but of particular interest is the interaction be-
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Figure 4 Loss of TRIP-1 in human lung fetal fibroblasts leads to decreased apoptosis in a collagen matrix. A: TUNEL staining in HLF-F cells
transfected with control siRNA (left) or TRIP-1 siRNA (right). Cells were transfected, and 2 days later embedded in a type I collagen matrix and
allowed to contract matrix for 5 days, then cells were recovered from the gel and staining performed as described in Methods. Staining in green
shows positive TUNEL, while blue corresponds to DAPI; B: Quantification of % positive TUNEL stained cells (apoptosis) based on analysis of pictures
like the ones shown in A. Experiment was repeated three times, one experiment is shown. Means ± SE shown (**P < 0.05, n = 3); C: control siRNA
or TRIP-1 siRNA-transfected cells were embedded in collagen matrix, gels were collected after 24 or 48 hours and lysed directly in sample buffer
(Laemli); western-blot for cleaved caspase 3 is shown. Actin is shown as a protein loading control; one representative Western-blot experiment is






Figure 3 Decreased α-SMA expression and less stress fibers in HLF-A transfected with TRIP-1 plasmid. HLF-A cells were left untreated or
treated with 5 ng/ml TGF-β1 in 0.5% FBS for 3 days, then transfected with V5-TRIP-1 plasmid and analyzed 2 days later. Panels A and B show
immunofluorescent stains of V5-transfected cells, stained with V5 antibody in green and α-SMA (panel A) or Rhodamine-Phalloidin (panel B) in
red. Blue corresponds to DAPI (nuclei). Experiment was performed three times and one representative experiment is shown.
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traction leading to decreased levels of phosphorylated
AKT (prosurvival form of AKT) and increased fibroblast
apoptosis. We evaluated TRIP-1′s role in modulating
AKT expression by measuring AKT levels in both TRIP-
1 siRNA-transfected and control siRNA-transfected
HLF-F. As seen in Figure 5A and 5B, the levels of phos-
phorylated AKT were increased in the TRIP-1 siRNA-
transfected HLF-F when compared to the control
siRNA-transfected HLF-F.
To further assess the role AKT plays in contractility
we investigated the role AKT expression has on α-SMA
expression. We attempted AKT siRNA transfection, but
transfection efficiency was very poor and seemed to
cause cell death (data not shown). Transfection with a
plasmid construct that works as a dominant negative
AKT was also toxic to the cells (not shown). We next
used Akt inhibitor II, a chemical inhibitor, to block AKT
signaling in TRIP-1 siRNA-transfected HLF-F. This in-
hibitor has been shown to block AKT activation [27],
and in HLF, a 2 hour treatment with the inhibitor is able




















































Figure 5 Loss of TRIP-1 is associated with increased phosphorylation
α-SMA expression in cells with low TRIP-1 expression. A: HLF-F were tr
were prepared and levels of phosphorylated Akt were analyzed by western
analysis of P-Akt levels normalized to total Akt in control siRNA-transfected
(**P < 0.05, n = 3); C: HLF-F were transfected with control siRNA or TRIP-1 si
inhibitor II for 2 days before lysates were prepared. Experiment was perform
control siRNA-transfected cells(left), TRIP-1 siRNA-transfected cells (middle)
D: Densitometric analysis of α-SMA normalized to tubulin from C, includingWestern blot (Additional file 1: Figure S3). Interestingly,
α-SMA expression was abrogated in HLF-F treated with
inhibitor compared to TRIP-1 siRNA transfected HLF-F
(Figure 5C and D). This suggests that TRIP-1 regulates
α-SMA expression through the AKT signaling pathway,
and activation of AKT is required for induction of α-
SMA.
Activated AKT mediates the enhanced collagen
contraction in human lung fibroblasts
The activation of the AKT pathway provides a survival
signal for fibroblasts and has been reported to be down-
regulated in fibroblasts in a collagen matrix [28]. We
assessed the role the AKT pathway plays in the fibro-
blast contractile response by transfecting HLF-F with a
control plasmid or pSG5-AKT GAG, an active form of
AKT (CA-AKT). As shown in Figure 6A and 6B, the
CA-AKT-transfected HLF-F demonstrated an enhanced
contractile response when compared to control LacZ-
transfected HLF-F. Also, the CA-AKT-transfected HLF-
F underwent less apoptosis when compared to control
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-blot. α-Tubulin was used as a loading control; B: Densitometric
(left) or TRIP-1 siRNA-transfected cells (right) with means ± SE shown
RNA, and treated right after transfection (or not) with 40 μM Akt
ed three times, and one representative experiment is shown, with
and TRIP-1 siRNA-transfected, Akt inhibitor II-treated cells (right);
three sets of samples, with means ± SE shown (**P < 0.05, n = 3).
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Figure 6 Increased Akt activity leads to increased contractility and protection from apoptosis in collagen gels. A: HLF-F transfected cells
with control plasmid HLF LacZ (pcDNA4.0-LacZ, left panel) or an active form of Akt HLF CA-AKT (pSG5-AKT GAG, right panel) were embedded in
collagen gels, and contraction was analyzed 4 days later; B: % area contracted in respect to original area after 4 days is shown based on analysis
of images like the ones shown in A); C: HLF-F transfected cells with control plasmid HLF LacZ (pcDNA4.0-LacZ, left panel) or an active form of Akt
HLF CA-AKT (pSG5-AKT GAG, right panel) were embedded in collagen gels, and TUNEL staining was performed after 4 days in collagen matrix;
D: % positive TUNEL cells obtained from analysis of pictures like those in B). Experiments were performed three times and one representative
experiment is shown for each type, with mean ± SE shown (**P < 0.05, n = 3).
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through AKT activation has in sustained collagen con-
tractile response.
Discussion
It is generally considered that the excessive fibrogenesis
and resultant extracellular matrix remodeling in patho-
logical fibrosis is due to the presence and persistent ac-
tivity of activated fibroblasts of the myofibroblast
phenotype and function [29-31]. This fibroblast pheno-
type is not only an avid synthesizer of extracellular
matrix, it also has enhanced collagen contraction ability,
in addition to being more resistant to apoptosis. In the
current work, we report that down-regulation of TRIP-1
expression in primary human lung fibroblasts has the
promotive effect of inducing trans-differentiation to
the myofibroblast phenotype and function, while over-
expression has inhibitory effects. Down-regulation ofTRIP-1 expression induces α-SMA expression and re-
sistance to apoptosis, along with an increased ability for
collagen contraction. Implicated mechanistically is a
TRIP-1 dependent rise in phosphorylated-AKT level that
leads to accumulation of α-SMA and prolongation of
cell survival, and therefore, the ability to contract a col-
lagen matrix. These findings are important because they
reveal TRIP-1 in a novel regulatory role of modulating
fibroblast acquisition of the phenotype and function as-
sociated with myofibroblasts—the chief perpetrator cell
in fibrosis. This may have implications in development
of potential therapies for pathological fibrosis.
The fibroblast’s acquisition of the myofibroblast pheno-
type, which is identified by accumulation of α-SMA, occurs
through multiple pathways, but TGFβ1/Smad3 plays the
central role [3,13,14]. Thus, excessive activation of the
TGFβ1/Smad3 pathway has been linked to wound fibrosis
and fibroblasts treated with TGFβ1 show induction of α-
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TRIP-1 in HLF previously treated with TGFβ1 represses α-
SMA expression, while knockdown of TRIP-1 in HLF
causes α-SMA induction—suggesting TRIP-1 regulates α-
SMA expression. The changes were evident at both tran-
scriptional and translational levels. However, a TRIP-1
mediated molecular pathway independent of TGFβ1 ligand
must be involved because this induction of α-SMA oc-
curred without TGFβ1 treatment and even after inhibiting
TGF beta receptor 1 kinase with SB431542 and Smad3
knockdown. Interestingly, we found AKT phosphorylation
was also increased in the siRNA TRIP-1 knockdown fibro-
blasts and that inhibiting AKT activation in these cells
blocked the α-SMA induction. AKT is important to cellular
activity such as cell growth and survival, and is upregulated
during normal epithelial wound healing [32]. Wang et al.
recently reported TRIP-1 interacts with AKT to modulate
its activity level and demonstrated a direct relationship be-
tween TRIP-1 expression and AKT activity [33]. In our pri-
mary human lung fibroblasts, we found TRIP-1 depletion
increased AKT activation which is in contrast to the direct
relationship observed by Wang et al. in their hepatocellular
carcinoma and transformed cell lines. This is not surprising
given that cancer cells are notorious for a deregulation in
their translation machinery. Since inhibition of TGF beta
receptor 1 activation of Smad3 with SB431542 and Smad3
knockdown did not abrogate the loss of TRIP-1 effect on
α-SMA induction but blocking AKT signaling did, TRIP-1
effects likely involve direct or signaling interaction with
downstream factors related to the AKT signaling pathway.
Fibroblasts of the myofibroblast phenotype are generally
considered to be more resistant to apoptosis and have in-
creased collagen contraction ability. Indeed, the ability of
myofibroblasts to resist apoptosis has been suggested as a
central event driving the development of fibrotic disease,
while appropriate termination of activated fibroblast-
mediated response leads to normal fibrogenesis. We found
that our human lung fibroblasts with down-regulated
TRIP-1 expression were more resistant to apoptosis, con-
sistent with the functional phenotype associated with trans-
differentiation to myofibroblasts. Although apoptotic sig-
naling in fibroblasts occurs through many pathways, it is
well established that fibroblasts incorporated in type 1 col-
lagen matrix have increased phosphorylated-AKT levels
through β1 integrin dependent activation of phosphatidyl-
nositol 3 kinase (PI3K) and integrin-linked kinase (ILK)
[34]. Over time, while the fibroblasts contract the collagen
matrix, this integrin pathway is down-regulated, leading to
decreased levels of phosphorylated-AKT, which ultimately
leads to fibroblast apoptosis. Nho et al. reported that when
PTEN, a major negative regulator of the PI3K/AKT signal
pathway, is not expressed in fibroblasts, phosphorylated-
AKT levels are elevated and fibroblasts are resistant to
collagen matrix contraction-induced apoptosis [28]. Ourresults demonstrate that TRIP-1 siRNA-transfected HLF-F
have an increased phosphorylated-AKT signaling. Further-
more, enhanced collagen contraction and decreased apop-
tosis in HLF-F transfected with active AKT plasmid
suggests apoptosis plays a central role in collagen contrac-
tion independently of α-SMA expression.
Conclusion
In summary, we found that down-regulating TRIP-1 ex-
pression in primary human lung fibroblasts induces α-SMA
expression, enhances resistance to apoptosis, and enhances
collagen contraction ability. These changes are consistent
with trans-differentiation to myofibroblast phenotype and
function. In contrast, TRIP-1 over-expression inhibits α-
SMA expression. Remarkably, loss of TRIP-1 effects is not
abrogated by blockage of TGFβ1 ligand activation of the
Smad3 pathway or by Smad3 knockdown. Rather a TRIP-1
mediated enhancement of AKT phosphorylation is impli-
cated as the mechanism. The importance of these findings
is that they reveal TRIP-1 as a novel regulator of fibroblast
acquisition of phenotype and function associated with
myofibroblasts and thus, a potential target in therapeutic
strategy aimed against pathological fibrosis.
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Additional file 1: Supplemental methods and figures. Western-blot-
Cells transfected with control siRNA or TRIP-1 siRNA were lysed 48 hours
after transfection, and western-blot was performed using antibodies
against caldesmon (rabbit monoclonal E89 from Abcam, 1:10,000) and
calponin (rabbit monoclonal EP798Y from Abcam, 1:10,000). Real-time
PCR-RNA was obtained from cells that had been transfected with control
siRNA or TRIP-1 siRNA and treated with TGFβ1 5 ng/ml for 48 hours.
Total RNA was isolated using Trizol, DNAse-treated, then processed for
First-Strand Synthesis with SuperScript (Life Technologies) and real-time
PCR was performed on BioRad MyIQ system using IQ SyberGreen-
Supermix from BioRad, Inc. Experiment was performed three times and
samples were run in triplicate. Figure Legends: Figure S1. Expression of
caldesmon and calponin by western-blot is increased in cells transfected
with TRIP-1 siRNA. Figure S2. Real-time PCR analysis of TGF-β
-dependent genes A) PAI-1 and B) CTGF in cells with decreased TRIP-1
expression, with or without TGFβ 48 hours treatment. Figure S3. AKT
inhibitor II treatment decreases phosphorylation of AKT. Cells in complete
media were treated with vehicle (DMSO) or 40 μM AKT inhibitor for 2
hours, then samples were made and SDS PAGE gels run, and
Western-Blot performed for P-AKT and Tubulin.
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